16:07 , Aug 10, 2018 |  BioCentury  |  Finance

Missing the obvious

Despite the vast amount of venture money being poured into innovation in healthcare, women’s health still remains an underserved market with significant untapped potential. The importance of this for public health is often overlooked in favor...
19:03 , Jun 22, 2018 |  BC Week In Review  |  Financial News

ObsEva raises $73M follow-on

Reproductive health company ObsEva S.A. (NASDAQ:OBSV) raised $73.1 million through the sale of 4.8 million shares at $15.39 in a follow-on underwritten by J.P. Morgan, Credit Suisse Securities (USA), Jefferies, Wedbush Securities and H.C. Wainwright....
20:13 , Jun 20, 2018 |  BC Extra  |  Financial News

ObsEva raises $73M on heels of linzagolix data

ObsEva S.A. (NASDAQ:OBSV) raised $73.1 million through the sale of 4.8 million shares at $15.39 in a follow-on underwritten by J.P. Morgan, Credit Suisse Securities (USA), Jefferies, Wedbush Securities and H.C. Wainwright. The price is...
18:01 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

ObsEva's nolasiban meets in Phase III to improve pregnancy rates

ObsEva S.A. (NASDAQ:OBSV) reported top-line data from the the Phase III IMPLANT2 trial in 778 women showing that a single 900 mg dose of oral nolasiban (formerly OBE001) met the primary endpoint of increasing the...
00:59 , Mar 30, 2017 |  BC Week In Review  |  Clinical News

Nolasiban: Ph III IMPLANT2 started

ObsEva began the double-blind, placebo-controlled, European Phase III IMPLANT2 trial to evaluate single doses of 900 mg oral nolasiban before fresh embryo transfer on day 3 or day 5 following egg retrieval in about 760...
00:39 , Jan 27, 2017 |  BC Extra  |  Financial News

ObsEva dips after $96.8M IPO

Women's health company ObsEva S.A. (NASDAQ:OBSV) lost $3.35 (22%) to $11.65 in its first day of trading after it raised $96.8 million through the sale of 6.5 million shares at $15 in an IPO underwritten...
23:16 , Dec 30, 2016 |  BC Extra  |  Financial News

Jounce, ObsEva file for IPOs

Cancer immunotherapy company Jounce Therapeutics Inc. (Cambridge, Mass.) and reproductive health play ObsEva S.A. (Geneva, Switzerland) each filed for IPOs on NASDAQ on Friday. Jounce proposed to raise up to $75 million in an offering underwritten...
19:54 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

Nolasiban: Ph II data

Top-line data from the double-blind, European Phase II IMPLANT trial in 247 women undergoing embryo transfer following in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) showed that a single dose of oral nolasiban given...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

IX-01: Phase IIa data

The double-blind, U.S. and Australian Phase IIa PEPIX trial in 88 patients with severe lifelong premature ejaculation showed that oral IX-01 given 1-6 hours prior to sexual activity significantly improved IELT by >3.5 fold vs....
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

OBE001: Phase II started

ObsEva began the double-blind, placebo-controlled, European Phase II TERM trial to evaluate oral OBE001 once daily for up to 7 days in 100 patients. ObsEva has exclusive, worldwide rights to OBE001 from Merck. ObsEva S.A.,...